Cargando…
The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases
Pharmacoepidemiology is used extensively in osteoporosis research and involves the study of the use and effects of drugs in large numbers of people. Randomized controlled trials are considered the gold standard in assessing treatment efficacy and safety. However, their results can have limited exter...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124176/ https://www.ncbi.nlm.nih.gov/pubmed/30283902 http://dx.doi.org/10.1002/jbm4.10051 |
_version_ | 1783352988938534912 |
---|---|
author | Alarkawi, Dunia Ali, M Sanni Bliuc, Dana Center, Jacqueline R Prieto‐Alhambra, Daniel |
author_facet | Alarkawi, Dunia Ali, M Sanni Bliuc, Dana Center, Jacqueline R Prieto‐Alhambra, Daniel |
author_sort | Alarkawi, Dunia |
collection | PubMed |
description | Pharmacoepidemiology is used extensively in osteoporosis research and involves the study of the use and effects of drugs in large numbers of people. Randomized controlled trials are considered the gold standard in assessing treatment efficacy and safety. However, their results can have limited external validity when applied to day‐to‐day patients. Pharmacoepidemiological studies aim to assess the effect/s of treatments in actual practice conditions, but they are limited by the quality, completeness, and inherent bias due to confounding. Sources of information include prospectively collected (primary) as well as readily available routinely collected (secondary) (eg, electronic medical records, administrative/claims databases) data. Although the former enable the collection of ad hoc measurements, the latter provide a unique opportunity for the study of large representative populations and for the assessment of rare events at relatively low cost. Observational cohort and case‐control studies, the most commonly implemented study designs in pharmacoepidemiology, each have their strengths and limitations. However, the choice of the study design depends on the research question that needs to be answered. Despite the many advantages of observational studies, they also have limitations. First, missing data is a common issue in routine data, frequently dealt with using multiple imputation. Second, confounding by indication arises because of the lack of randomization; multivariable regression and more specific techniques such as propensity scores (adjustment, matching, stratification, trimming, or weighting) are used to minimize such biases. In addition, immortal time bias (time period during which a subject is artefactually event‐free by study design) and time‐varying confounding (patient characteristics changing over time) are other types of biases usually accounted for using time‐dependent modeling. Finally, residual “uncontrolled” confounding is difficult to assess, and hence to account for it, sensitivity analyses and specific methods (eg, instrumental variables) should be considered. © 2018 The Authors JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research. |
format | Online Article Text |
id | pubmed-6124176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61241762018-10-03 The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases Alarkawi, Dunia Ali, M Sanni Bliuc, Dana Center, Jacqueline R Prieto‐Alhambra, Daniel JBMR Plus Review Pharmacoepidemiology is used extensively in osteoporosis research and involves the study of the use and effects of drugs in large numbers of people. Randomized controlled trials are considered the gold standard in assessing treatment efficacy and safety. However, their results can have limited external validity when applied to day‐to‐day patients. Pharmacoepidemiological studies aim to assess the effect/s of treatments in actual practice conditions, but they are limited by the quality, completeness, and inherent bias due to confounding. Sources of information include prospectively collected (primary) as well as readily available routinely collected (secondary) (eg, electronic medical records, administrative/claims databases) data. Although the former enable the collection of ad hoc measurements, the latter provide a unique opportunity for the study of large representative populations and for the assessment of rare events at relatively low cost. Observational cohort and case‐control studies, the most commonly implemented study designs in pharmacoepidemiology, each have their strengths and limitations. However, the choice of the study design depends on the research question that needs to be answered. Despite the many advantages of observational studies, they also have limitations. First, missing data is a common issue in routine data, frequently dealt with using multiple imputation. Second, confounding by indication arises because of the lack of randomization; multivariable regression and more specific techniques such as propensity scores (adjustment, matching, stratification, trimming, or weighting) are used to minimize such biases. In addition, immortal time bias (time period during which a subject is artefactually event‐free by study design) and time‐varying confounding (patient characteristics changing over time) are other types of biases usually accounted for using time‐dependent modeling. Finally, residual “uncontrolled” confounding is difficult to assess, and hence to account for it, sensitivity analyses and specific methods (eg, instrumental variables) should be considered. © 2018 The Authors JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research. John Wiley and Sons Inc. 2018-04-30 /pmc/articles/PMC6124176/ /pubmed/30283902 http://dx.doi.org/10.1002/jbm4.10051 Text en © 2018 The Authors JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Alarkawi, Dunia Ali, M Sanni Bliuc, Dana Center, Jacqueline R Prieto‐Alhambra, Daniel The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases |
title | The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases |
title_full | The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases |
title_fullStr | The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases |
title_full_unstemmed | The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases |
title_short | The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases |
title_sort | challenges and opportunities of pharmacoepidemiology in bone diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124176/ https://www.ncbi.nlm.nih.gov/pubmed/30283902 http://dx.doi.org/10.1002/jbm4.10051 |
work_keys_str_mv | AT alarkawidunia thechallengesandopportunitiesofpharmacoepidemiologyinbonediseases AT alimsanni thechallengesandopportunitiesofpharmacoepidemiologyinbonediseases AT bliucdana thechallengesandopportunitiesofpharmacoepidemiologyinbonediseases AT centerjacqueliner thechallengesandopportunitiesofpharmacoepidemiologyinbonediseases AT prietoalhambradaniel thechallengesandopportunitiesofpharmacoepidemiologyinbonediseases AT alarkawidunia challengesandopportunitiesofpharmacoepidemiologyinbonediseases AT alimsanni challengesandopportunitiesofpharmacoepidemiologyinbonediseases AT bliucdana challengesandopportunitiesofpharmacoepidemiologyinbonediseases AT centerjacqueliner challengesandopportunitiesofpharmacoepidemiologyinbonediseases AT prietoalhambradaniel challengesandopportunitiesofpharmacoepidemiologyinbonediseases |